Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert, James R. Henry, John H. Dodd, Scott A. Wadsworth, Druie E. Cavender, Gilbert C. Olini, Bohumila Fahmy, John J. Siekierka

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

Original languageEnglish (US)
Pages (from-to)347-350
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume13
Issue number3
DOIs
StatePublished - Feb 1 2003

Fingerprint

p38 Mitogen-Activated Protein Kinases
Cytokines
Interleukin-1
Crohn Disease
Rheumatoid Arthritis

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Rupert, K. C., Henry, J. R., Dodd, J. H., Wadsworth, S. A., Cavender, D. E., Olini, G. C., ... Siekierka, J. J. (2003). Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters, 13(3), 347-350. https://doi.org/10.1016/S0960-894X(02)01020-X
Rupert, Kenneth C. ; Henry, James R. ; Dodd, John H. ; Wadsworth, Scott A. ; Cavender, Druie E. ; Olini, Gilbert C. ; Fahmy, Bohumila ; Siekierka, John J. / Imidazopyrimidines, potent inhibitors of p38 MAP kinase. In: Bioorganic and Medicinal Chemistry Letters. 2003 ; Vol. 13, No. 3. pp. 347-350.
@article{b208462ab5a744a29ab597039fb901cf,
title = "Imidazopyrimidines, potent inhibitors of p38 MAP kinase",
abstract = "The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.",
author = "Rupert, {Kenneth C.} and Henry, {James R.} and Dodd, {John H.} and Wadsworth, {Scott A.} and Cavender, {Druie E.} and Olini, {Gilbert C.} and Bohumila Fahmy and Siekierka, {John J.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0960-894X(02)01020-X",
language = "English (US)",
volume = "13",
pages = "347--350",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "3",

}

Rupert, KC, Henry, JR, Dodd, JH, Wadsworth, SA, Cavender, DE, Olini, GC, Fahmy, B & Siekierka, JJ 2003, 'Imidazopyrimidines, potent inhibitors of p38 MAP kinase', Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 3, pp. 347-350. https://doi.org/10.1016/S0960-894X(02)01020-X

Imidazopyrimidines, potent inhibitors of p38 MAP kinase. / Rupert, Kenneth C.; Henry, James R.; Dodd, John H.; Wadsworth, Scott A.; Cavender, Druie E.; Olini, Gilbert C.; Fahmy, Bohumila; Siekierka, John J.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 13, No. 3, 01.02.2003, p. 347-350.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Imidazopyrimidines, potent inhibitors of p38 MAP kinase

AU - Rupert, Kenneth C.

AU - Henry, James R.

AU - Dodd, John H.

AU - Wadsworth, Scott A.

AU - Cavender, Druie E.

AU - Olini, Gilbert C.

AU - Fahmy, Bohumila

AU - Siekierka, John J.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

AB - The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0037330356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037330356&partnerID=8YFLogxK

U2 - 10.1016/S0960-894X(02)01020-X

DO - 10.1016/S0960-894X(02)01020-X

M3 - Article

C2 - 12565927

AN - SCOPUS:0037330356

VL - 13

SP - 347

EP - 350

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 3

ER -

Rupert KC, Henry JR, Dodd JH, Wadsworth SA, Cavender DE, Olini GC et al. Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters. 2003 Feb 1;13(3):347-350. https://doi.org/10.1016/S0960-894X(02)01020-X